A Phase 1 Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2016
At a glance
- Drugs Gilteritinib (Primary)
- Indications Acute myeloid leukaemia; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 17 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 26 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 15 Oct 2015 New trial record